NANOBIOSE | Linksium
Back to portfolio

NANOBIOSE

Incorporated startups

Labs-on-a-chip for early drug assessment

profilePhoto   Philippe Mattia
Linksium Contact Philippe Mattia +33 (0)4 57 13 81 65 philippe.mattia@linksium.fr
NANOBIOSE Damien Fleury, CEO +33 (0)4 79 26 67 57 damienfleury@nanobiose.com

Benefits

  • Control of R&D costs
  • Impact of R&D strategy
  • Flexibility
  • Rapidity

Key words

  • Real-time & kinetic capture of secretion of biomarkers
  • Multiplexing
  • Nanodrugs
  • Immunotoxicology

Institution

  • UGA

Linksium Continuum

  • Incubation
  • Acceleration

Results

  • Incorporated startups

Context

90% of new drugs fail clinical trials on humans, which results in substantial financial losses for the pharmaceutical industry. This is mainly due to inadequate assessment during the early phases of R&D through the lack of predictive tests for effects on humans.

Technology

Based on microfluidics, the Nanobiose lab-on-a-chip integrates 3D cell culture technologies (imitating physiological conditions more effectively) and a removable biosensor that enables the multiplex analysis of biomarkers (up to 9) by measuring fluorescence.

Advantages

  • Combination in a single experiment of 3D cell culture
  • Real-time capture of biomarkers secreted by the cells
  • Unique results (the kinetics of the biomarkers)
  • Significant saving in man-hours (> 50%)

State of progress

The POC was created with the support of BPI and thanks to a FrenchTech Emergence grant. Lab-on-a-chip prototypes and biosensors (5 cytokines tested) were produced and are currently used to develop a first application concerning a 3D model for the inflammation of human macrophages.

Applications

SecretCells® also enables researchers to assess the potential effects of their candidate drugs more rapidly and efficiently by creating a direct link between potential toxicity and efficacy.